目的 分析2018-2019年焦作市第二人民醫(yī)院黃芪注射液的使用情況，為促進黃芪注射液的臨床合理應(yīng)用提供參考。方法 回顧性調(diào)查焦作市第二人民醫(yī)院2018年1月-2019年6月使用黃芪注射液的病歷，記錄患者基本情況、藥品信息、藥品使用情況等進行統(tǒng)計分析。結(jié)果 共追蹤837份病例，以男性為主，年齡集中在60歲以上的患者，占60.81%。黃芪注射液的使用科室主要為中醫(yī)科和腫瘤科，構(gòu)成比分別為28.43%、23.54%。黃芪注射液的用法均為靜脈滴注，用量集中10、20 mL/d，共606例，構(gòu)成比為72.40%。用藥療程主要分布于≤ 7、8~15 d，構(gòu)成比分別為37.63%、51.49%；與參麥注射液和血栓通注射液的聯(lián)用最多，構(gòu)成比分別為35.48%、29.03%。結(jié)論 2018-2019年焦作市第二人民醫(yī)院黃芪注射液的應(yīng)用基本合理，臨床使用中存在不辨證論治的情況，為提高中藥的臨床療效，避免不良反應(yīng)，在使用過程中應(yīng)辨證論治，提升其臨床應(yīng)用的合理性。

Objective To analyze the clinical use of Huangqi Injection in the Second People's Hospital of Jiaozuo from 2018 to 2019, and to provide reference for promoting the rational clinical application of Huangqi Injection. Methods Medical records using Huangqi Injection in the Second People's Hospital of Jiaozuo from 2018 to 2019 were retrospectively analyzed, recording the basic situation of patients, drug information, and drug use. Results 837 Cases were tracked, and most of them were male. The ages of moat patients were above 60 years old, accounting for 60.81%. The main departments using Huangqi Injection were Department of TCM and Department of oncology, accounting for 28.43% and 23.54%. Huangqi Injection was intravenous drip, and the dose was 10 and 20 mL/d, and there were 606 cases, accounting for 72.40%.The treatment course was mainly distributed in ≤ 7 and 8-15 d, with the composition ratio of 37.63% and 51.49%. The combination of Shenmai Injection and Xueshuantong Injection was more, accounting for 35.48% and 29.03%. Conclusion The application of Huangqi Injection in the Second People's Hospital of Jiaozuo from 2018 to 2019 is basically reasonable. There are cases of non-dialectical treatment in clinical use, in order to improve the clinical curative effect of traditional Chinese medicine, and avoid adverse reactions. Therefore, syndrome differentiation should be treated in the process of use to improve the rationality of its clinical application.

R972